Lung cancer
The mandated need for an effective diagnostic test
-
More Americans (160,000) will die from lung cancer this year than from breast, prostate, and colorectal cancer combined (American Cancer Society).
1.6 Million
Will die from lung cancer this year worldwide
Current 5 year
survival rate:
-
The lack of an early detection method is a key factor contributing to this low rate. The current methods of diagnosis are proven to be ineffective and expensive.
17.7%
55.2%
-
With our detection test via breath analysis, we can target at risk groups and have a much higher chance to pinpoint the cancer early.
5 year survival rate
with early detection:
Percent of Cases by Stage for lung cancer
5%
Unknown
Unstaged
16%
Localized
Confined to primary site
22%
Regional
Spread to regional lymph nodes
57%
Distant
Cancer has metastasized
-
Only 16% of screenings happen when the cancer is localized or in its early phase. Detecting the cancer too late greatly reduces the chance of survival.
In part, this is due to the fact that a robust and cost-effective diagnostic test for lung cancer when it is at the most treatable (i.e., early) stage does not presently exist.
